Patti M G, Arcerito M, Feo C V, Worth S, De Pinto M, Gibbs V C, Gantert W, Tyrrell D, Ferrell L F, Way L W
Department of Surgery, University of California, San Francisco, San Francisco, California 94143-0788, USA.
J Gastrointest Surg. 1999 Jul-Aug;3(4):397-403; discussion 403-4. doi: 10.1016/s1091-255x(99)80056-0.
Barrett's metaplasia can develop in patients with gastroesophageal reflux disease (GERD), and metaplasia can evolve into dysplasia and adenocarcinoma. The optimal treatment for Barrett's metaplasia and dysplasia is still being debated. The study reported herein was designed to assess the following: (1) the incidence of Barrett's metaplasia among patients with GERD; (2) the ability of laparoscopic fundoplication to control symptoms in patients with Barrett's metaplasia; (3) the results of esophagectomy in patients with high-grade dysplasia; and (4) the character of endoscopic follow-up programs of patients with Barrett's disease being managed by physicians throughout a large geographic region (northern California). Five-hundred thirty-five patients evaluated between October 1989 and February 1997 at the University of California San Francisco Swallowing Center had a diagnosis of GERD established by upper gastrointestinal series, endoscopy, manometry, and pH monitoring. Thirty-eight symptomatic patients with GERD and Barrett's metaplasia underwent laparoscopic fundoplication. Eleven other consecutive patients with high-grade dysplasia underwent transhiatal esophagectomies. Barrett's metaplasia was present in 72 (13%) of the 535 patients with GERD. The following results were achieved in patients who underwent laparoscopic fundoplication (n = 38): Heartburn resolved in 95% of patients, regurgitation in 93% of patients, and cough in 100% of patients. With regard to transhiatal esophagectomy (n = 11), the average duration of the operation was 339 +/- 89 minutes. The only significant complications were two esophageal anastomotic leaks, both of which resolved without sequelae. Mean hospital stay was 14 +/- 5 days. There were no deaths. The specimens showed high-grade dysplasia in seven patients and invasive adenocarcinoma (undiagnosed preoperatively) in four (36%). These results can be summarized as follows: (1) Barrett's metaplasia was present in 13% of patients with GERD being evaluated at a busy diagnostic center; (2) laparoscopic fundoplication was highly successful in controlling symptoms of GERD in patients with Barrett's metaplasia; (3) in patients with high-grade dysplasia esophagectomy was performed safely (invasive cancer had eluded preoperative endoscopic biopsies in one third of these patients); and (4) even though periodic endoscopic examination of Barrett's disease is universally recommended, this was actually done in fewer than two thirds of patients being managed by a large number of independent physicians in this geographic area.
巴雷特化生可发生于胃食管反流病(GERD)患者,化生可发展为发育异常和腺癌。巴雷特化生和发育异常的最佳治疗方法仍存在争议。本文所报告的研究旨在评估以下内容:(1)GERD患者中巴雷特化生的发生率;(2)腹腔镜胃底折叠术控制巴雷特化生患者症状的能力;(3)高级别发育异常患者行食管切除术的结果;(4)在一个广大地理区域(北加利福尼亚)由医生管理的巴雷特病患者内镜随访项目的特点。1989年10月至1997年2月期间,在加利福尼亚大学旧金山分校吞咽中心接受评估的535例患者通过上消化道造影、内镜检查、测压和pH监测确诊为GERD。38例有症状的GERD和巴雷特化生患者接受了腹腔镜胃底折叠术。另外11例连续的高级别发育异常患者接受了经胸食管切除术。535例GERD患者中有72例(13%)存在巴雷特化生。接受腹腔镜胃底折叠术的患者(n = 38)取得了以下结果:95%的患者烧心症状缓解,93%的患者反流症状缓解,100%的患者咳嗽症状缓解。关于经胸食管切除术(n = 11),手术平均时长为339 +/- 89分钟。仅有的严重并发症为2例食管吻合口漏,均无后遗症而愈。平均住院时间为14 +/- 5天。无死亡病例。标本显示7例患者为高级别发育异常,4例(36%)为浸润性腺癌(术前未诊断出)。这些结果可总结如下:(1)在一家繁忙的诊断中心接受评估的GERD患者中,13%存在巴雷特化生;(2)腹腔镜胃底折叠术在控制巴雷特化生患者的GERD症状方面非常成功;(3)对于高级别发育异常患者,食管切除术实施安全(这些患者中有三分之一术前内镜活检未发现浸润癌);(4)尽管普遍建议对巴雷特病进行定期内镜检查,但在该地理区域由大量独立医生管理的患者中,实际接受检查的患者不到三分之二。
J Gastrointest Surg. 1999
Adv Surg. 1999
Am J Gastroenterol. 2004-2
Scand J Gastroenterol. 2012-1
Arch Surg. 1994-6
Ann Thorac Surg. 2004-2
World J Surg. 2018-6
World J Surg. 2015-3
Updates Surg. 2011-2-10
World J Gastroenterol. 2010-8-14
J Gastrointest Surg. 2009-6-10
J Gastrointest Surg. 2007-12
World J Surg. 2004-3
J Gastrointest Surg. 1997
J Thorac Cardiovasc Surg. 1996-6
J Thorac Cardiovasc Surg. 1993-3
J Thorac Cardiovasc Surg. 1993-1